Cellectis Announces Participation in Upcoming Investor Conferences

Cellectis (NASDAQ: CLLS), a clinical-stage gene-editing company, announced participation in several upcoming investor conferences.

Rhea-AI Summary

Cellectis (NASDAQ: CLLS), a clinical-stage gene-editing company, announced participation in several upcoming investor conferences. These include the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, 2026, the Baird 2026 Global Healthcare Conference in New York on September 15, 2026 (with a company presentation from 12:50 to 1:20 p.m. ET), Barclays Biotech 1x1 Day in New York on October 6, 2026, the Stifel 2026 Healthcare Conference in New York from November 10-12, 2026, and the Jefferies Global Healthcare Conference in London from November 16-19, 2026. Cellectis’ management will be available for investor meetings at these events, and any available webcasts will be posted in the investors section of its website.

Argus Sep 2 session 2 alerts

-1.52% close to close 0.3x rel. volume Open Argus

Details

News Market Reaction – CLLS

-2.5% Trough Tracked

$320.29M Market Cap

On Sep 2, the first trading day after this news, CLLS closed 1.52% below the previous close. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner recorded 2 alerts in the available session data.

Data tracked by StockTitan Argus for the Sep 2 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference – Boston, MA
September 10, 2026

Baird 2026 Global Healthcare Conference – New York
September 15, 2026
Company presentation at 12:50 - 1:20 p.m. ET

Fall Focus: Barclays Biotech 1x1 Day – New York
October 6, 2026

Stifel 2026 Healthcare Conference – New York
November 10-12, 2026

Jefferies Global Healthcare Conference – London
November 16-19, 2026

Cellectis' management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at investors@cellectis.com

Any available webcast will be posted to the Company's website at https://www.cellectis.com/en/investors/events-and-webcasts/.

About Cellectis     
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• PRESS RELEASE_Q4 2026 conference attendance_EN

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which investor conferences will Cellectis (NASDAQ: CLLS) attend in late 2026?

Cellectis will attend investor conferences hosted by Wells Fargo, Baird, Barclays, Stifel, and Jefferies in Boston, New York, and London. According to Cellectis, these events run from September 10 through November 19, 2026, covering multiple key healthcare investor forums.

When is Cellectis presenting at the Baird 2026 Global Healthcare Conference (CLLS)?

Cellectis is scheduled to present at the Baird 2026 Global Healthcare Conference on September 15, 2026, from 12:50 to 1:20 p.m. ET. According to Cellectis, this presentation takes place in New York as part of the broader investor event.

How can investors meet with Cellectis management at the 2026 healthcare conferences?

Investors can request meetings with Cellectis management through each conference’s representatives or by emailing investors@cellectis.com. According to Cellectis, its management team will be available for one-on-one discussions throughout the scheduled conferences in the United States and London.

Will Cellectis (CLLS) provide webcasts for its 2026 investor conference appearances?

Cellectis plans to post any available webcasts from these conferences on its investor events and webcasts webpage. According to Cellectis, investors should visit https://www.cellectis.com/en/investors/events-and-webcasts/ to access recordings or live streams when made available.

What are the dates and locations of Cellectis’ November 2026 healthcare conferences?

In November 2026, Cellectis will join the Stifel Healthcare Conference in New York from November 10-12 and the Jefferies Global Healthcare Conference in London from November 16-19. According to Cellectis, both events feature opportunities for investor meetings.

What type of company is Cellectis (NASDAQ: CLLS, Euronext: ALCLS)?

Cellectis is a clinical-stage biotechnology company focused on gene-editing-based cell and gene therapies. According to Cellectis, it uses an allogeneic CAR T approach and maintains in-house manufacturing capabilities, operating from Paris, New York, and Raleigh, North Carolina.